Skip to main content
. 2020 Jun 2;37(7):1675–1683. doi: 10.1007/s10815-020-01809-3

Table 2.

Clinical outcome of IVF-PGT-M in carriers of the FRAX premutation and the FRAX mutation

FRAX premutation cycles FRAX full mutation cycles p value
(n = 56) (n = 30)
Protocol (%)

Long Agonist

Antagonist

Short agonist

34 (60.7)

21 (37.5)

1 (1.9)

15 (50)

15 (50)

-
Stimulation outcome

Satisfying ovarian response (%)

Cycle cancellation (%)

48 (85.7%)

8 (14.5%)

25 (83.3%)

5 (16.7%)

0.7703
Mean ovarian stimulation duration (days) (SD) 10.1 (2.1) 9.7 (1.1) 0.2364
Mean total dose of FSH/cycle (IU)(SD) 2740 (857) 1944 (857) 0.0069
Mean estradiol peak (pg/mL) (SD) 1996 (1242) 2529 (1595) 0.1065
Mean number of retrieved oocytes (SD) 10.9 (4.9) 10.6 (5.1) 0.765
Mean number of metaphase II oocytes (SD) 7.1 (5.0) 6.6 (4.2) 0.871
Mean number of day 3 embryos (SD) 5.6 (4.1) 4.9 (3.5) 0.554
Mean number of embryos to transfer after genetic analysis (SD) 1.7 (1.1) 2 (1.5) 0.4253
Mean number of transferred embryos after genetic analysis (SD) 1.5 (0.5) 1.6 (0.5) 0.5020
Pregnancy rate/started cycle (%) 13/56 (23.2%) 2/30 (6.7%) 0.0787
Pregnancy rate/oocyte retrieval (%) 13/48 (27.1%) 2/25 (8.0%) 0.0851
Pregnancy rate/embryo transfer (%) 13/35 (37.1%) 2/15 (13.3%) 0.1076